23andMe Holding Co. (ME)
Bid | n/a |
Market Cap | 13.34M |
Revenue (ttm) | 208.78M |
Net Income (ttm) | -382.87M |
EPS (ttm) | -17.39 |
PE Ratio (ttm) | -0.03 |
Forward PE | -0.07 |
Analyst | Hold |
Ask | n/a |
Volume | 29,751,445 |
Avg. Volume (20D) | 4,158,486 |
Open | 0.75 |
Previous Close | 0.61 |
Day's Range | 0.61 - 0.75 |
52-Week Range | 0.48 - 12.76 |
Beta | 1.20 |
About ME
23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact respo...
Analyst Forecast
According to 1 analyst ratings, the average rating for ME stock is "Hold." The 12-month stock price forecast is $9.4, which is an increase of 1450.39% from the latest price.
Stock Forecasts
2 weeks ago · proactiveinvestors.com
23andMe shares jump as US judge allows sale of customer data23andMe (NASDAQ:ME) shares rebounded more than 60% on Thursday after a US judge confirmed the genetic testing company is allowed to sell customer data as part of its Chapter 11 bankruptcy proceedings....